Number of the records: 1

Prostate Health Index in Prediction of Postoperative Gleason Score Upgrading

SYSNO ASEP	0504666
Document Type	A - Abstract
R&D Document Type	The record was not marked in the RIV
R&D Document Type	Není vybrán druh dokumentu
Title	Prostate Health Index in Prediction of Postoperative Gleason Score Upgrading
Author(s)	Fuchsová, R. (CZ) Topolčan, O. (CZ) Pecen, Ladislav (UIVT-O)_{RID, SAI, ORCID} Dolejšová, O. (CZ) Hora, M. (CZ) Kučera, R. (CZ) Eret, V. (CZ)
Source Title	Clinical Chemistry and Laboratory Medicine - ISSN 1434-6621 Roč. 55, s2 (2017), S1277
Number of pages	1 s.
Action	IFCC-WorldLab 2017
Event date	22.10.2017 - 25.10.2017
VEvent location	Durban
Country	ZA - South Africa
Event type	WRD
Language	eng - English
Country	DE - Germany
DOI	10.1515/cclm-2017-7047
Annotation	BACKGROUND-AIM: The biopsy Gleason score (GS) value affects the choice of optimal treatment of prostate cancer. Biopsy GS is, however, inaccurate. Prostate health index (PHI) in a number of studies has demonstrated a close correlation with the aggressiveness of the prostate tumor found. PHI could therefore help in choosing an optimal treatment. Aim: Evaluate the contribution of PHI in prediction of upgrading or downgrading of GS in patients with prostate cancer indicated for radical prostatectomy. METHODS: We determined the PHI (Beckman-Coulter) in a group of 320 patients from the Urology Clinic of University Hospital in Pilsen with biopsy-proven prostate cancer and indicated for radical prostatectomy. We made a comparison between the bioptic GS and the postoperative (histological) GS in relation to the PHI level. RESULTS: PHI correlates much better with the postoperative histology than with the biopsy result. The postoperative GS value was the same as the bioptic GS value in only 145 (45.3%) patients. In the case of correlation of PHI with the GS6 biopsy result, the median was 54 but only 43 in postoperative histology. 56.6% of patients with the GS6 biopsy exhibited a postoperative GS higher than 6. CONCLUSIONS: PHI is not only a diagnostic marker of prostate cancer but also a marker of aggression, and is a useful tool for urologists in predicting the upgrading of GS in patients with prostate cancer. It therefore significantly contributes to the decision on the optimal choice of treatment strategy, especially for low-risk patients with GS 6. Supported by Ministry of Health, Czech Republic - conceptual development of research organization (Faculty Hospital in Pilsen - FNPl, 00669806).
Workplace	Institute of Computer Science
Contact	Tereza Šírová, sirova@cs.cas.cz, Tel.: 266 053 800
Year of Publishing	2020

Number of the records: 1